SCHEMBL15326526

SCHEMBL15326526

CN(C)c1ccc(S(=O)(=O)NCCn2nnnc2NC(=O)c2cccc(Cl)c2)c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HDAC4 P56524 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HTR3A P46098 1/20 0.40
MAPT P10636 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39
HTR1A P08908 2/20 0.39
EDNRA P25101 1/20 0.38
FUCA1 P04066 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15326553 0.96 HDAC4 (0.46) LMNAKDM4ETDP1HDAC4HDAC10
SCHEMBL15326624 0.88 EDNRA (0.46) LMNAKDM4ETDP1HDAC4HDAC10
SCHEMBL15326625 0.86 HDAC4 (0.44) LMNAKDM4ETDP1HDAC4HDAC10
SCHEMBL15326530 0.84 ALDH1A1 (0.44) LMNAKDM4ETDP1ALDH1A1NPC1
SCHEMBL16087862 0.83 LMNA (0.43) LMNAKDM4ETDP1ALDH1A1NPC1
SCHEMBL15323661 0.82 LMNA (0.48) LMNAKDM4ETDP1ALDH1A1NPC1
SCHEMBL15326626 0.82 ALDH1A1 (0.45) LMNAKDM4ETDP1ALDH1A1NPC1
SCHEMBL15326527 0.82 KDM4E (0.44) LMNAKDM4ETDP1ALDH1A1NPC1
SCHEMBL15326554 0.81 HDAC4 (0.46) HDAC4HDAC10HDAC6HDAC5NPC1
SCHEMBL15326561 0.81 NPC1 (0.50) LMNAKDM4ETDP1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975288-B2 F2 derivatives as antibacterial agents THE PENN STATE RESEARCH FOUNDATION (US) 2015-03-10 US disclosed
US-8975288-B2 F2 derivatives as antibacterial agents THE PENN STATE RESEARCH FOUNDATION (US) 2015-03-10 US disclosed
US-20140275192-A1 F2 DERIVATIVES AS ANTIBACTERIAL AGENTS THE PENN STATE RESEARCH FOUNDATION 2014-09-18 US disclosed
US-20140275192-A1 F2 DERIVATIVES AS ANTIBACTERIAL AGENTS THE PENN STATE RESEARCH FOUNDATION 2014-09-18 US disclosed
WO-2013154793-A1 F2 DERIVATIVES AS ANTIBACTERIAL AGENTS THE PENN STATE RESEARCH FOUNDATION (US) 2013-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275192-A1 F2 DERIVATIVES AS ANTIBACTERIAL AGENTS NR2C2, H1-10, NR2F2 LMNA 4547/4885KDM4E 3660/4885TDP1 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.